Terms: = Lung cancer AND CDH1, uvomorulin, 999, P12830, ENSG00000039068, CDHE, Arc-1, UVO, LCAM, CD324, ECAD AND Treatment
116 results:
1. Exploring the Mechanism of Zilongjin in Treating lung Adenocarcinoma Based on Network Pharmacology Combined with Experimental Verification.
Zhang K; Chen X
Crit Rev Immunol; 2024; 44(5):27-40. PubMed ID: 38618726
[TBL] [Abstract] [Full Text] [Related]
2. Trends and Disparities in Curative-Intent treatment for Early-Stage Non-Small Cell lung cancer: A Population-Based Analysis of Surgery and SBRT.
Liu Q; Medina HN; Rodriguez E; Jacobs KT; Brown C; Koru-Sengul T; Lopes G; Pinheiro PS
Cancer Epidemiol Biomarkers Prev; 2024 Apr; 33(4):489-499. PubMed ID: 38252069
[TBL] [Abstract] [Full Text] [Related]
3. CXCR4-directed PET/CT with [
Dreher N; Hahner S; Fuß CT; Schlötelburg W; Hartrampf PE; Serfling SE; Schirbel A; Samnick S; Higuchi T; Weich A; Lapa C; Rosenwald A; Buck AK; Kircher S; Werner RA
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1383-1394. PubMed ID: 38082196
[TBL] [Abstract] [Full Text] [Related]
4. Dose to Organ at Risk and its Characteristic Variation with the Clinically Used Different Prescription Levels for Early-stage Left-sided Breast cancer.
Haldar S; Sarkar B; Dixit A
Clin Oncol (R Coll Radiol); 2024 Jan; 36(1):21-29. PubMed ID: 38040550
[TBL] [Abstract] [Full Text] [Related]
5. Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC.
Gohlke L; Alahdab A; Oberhofer A; Worf K; Holdenrieder S; Michaelis M; Cinatl J; Ritter CA
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834189
[TBL] [Abstract] [Full Text] [Related]
6. Nivolumab as maintenance therapy following platinum-based chemotherapy in EGFR-mutant lung cancer patients after tyrosine kinase inhibitor failure: A single-arm, open-label, phase 2 trial.
Kim J; Choi CM; Ji W; Lee JC
Thorac Cancer; 2023 Nov; 14(31):3080-3088. PubMed ID: 37699785
[TBL] [Abstract] [Full Text] [Related]
7. Preoperative predicting invasiveness of lung adenocarcinoma manifesting as ground-glass nodules based on multimodal images of dual-layer spectral detector CT radiomics models.
Chang Y; Xing H; Shang Y; Liu Y; Yu L; Dai H
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15425-15438. PubMed ID: 37642725
[TBL] [Abstract] [Full Text] [Related]
8. Brucea javanica oil inhibits tongue squamous cell invasion and metastasis by regulating miR-138-EZH2 pathway.
Jiang L; Zhou J; Wu Y; Zhou L; Zhang C; Zhu J; Fang Z; Shao Y; Wang W
J Stomatol Oral Maxillofac Surg; 2023 Dec; 124(6S):101611. PubMed ID: 37619672
[TBL] [Abstract] [Full Text] [Related]
9. Deep Learning for Predicting Effect of Neoadjuvant Therapies in Non-Small Cell lung Carcinomas With Histologic Images.
Terada K; Yoshizawa A; Liu X; Ito H; Hamaji M; Menju T; Date H; Bise R; Haga H
Mod Pathol; 2023 Nov; 36(11):100302. PubMed ID: 37580019
[TBL] [Abstract] [Full Text] [Related]
10. Clinical evaluation of atlas-based auto-segmentation in breast and nodal radiotherapy.
Welgemoed C; Spezi E; Riddle P; Gooding MJ; Gujral D; McLauchlan R; Aboagye EO
Br J Radiol; 2023 Sep; 96(1149):20230040. PubMed ID: 37493138
[TBL] [Abstract] [Full Text] [Related]
11. Novel models by machine learning to predict prognosis of breast cancer brain metastases.
Li C; Liu M; Zhang Y; Wang Y; Li J; Sun S; Liu X; Wu H; Feng C; Yao P; Jia Y; Zhang Y; Wei X; Wu F; Du C; Zhao X; Zhang S; Qu J
J Transl Med; 2023 Jun; 21(1):404. PubMed ID: 37344847
[TBL] [Abstract] [Full Text] [Related]
12. A Novel Quantum Dots-Based Fluorescent Sensor for Determination of the Anticancer Dacomitinib: Application to Dosage Forms.
Alossaimi MA; Elmansi H; Alajaji M; Altharawi A; Altamimi ASA; Magdy G
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903599
[TBL] [Abstract] [Full Text] [Related]
13. Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial.
Aokage K; Suzuki K; Saji H; Wakabayashi M; Kataoka T; Sekino Y; Fukuda H; Endo M; Hattori A; Mimae T; Miyoshi T; Isaka M; Yoshioka H; Nakajima R; Nakagawa K; Okami J; Ito H; Kuroda H; Tsuboi M; Okumura N; Takahama M; Ohde Y; Aoki T; Tsutani Y; Okada M; Watanabe SI;
Lancet Respir Med; 2023 Jun; 11(6):540-549. PubMed ID: 36893780
[TBL] [Abstract] [Full Text] [Related]
14. Stabilization of E-cadherin adhesions by COX-2/GSK3β signaling is a targetable pathway in metastatic breast cancer.
Balamurugan K; Poria DK; Sehareen SW; Krishnamurthy S; Tang W; McKennett L; Padmanaban V; Czarra K; Ewald AJ; Ueno NT; Ambs S; Sharan S; Sterneck E
JCI Insight; 2023 Mar; 8(6):. PubMed ID: 36757813
[TBL] [Abstract] [Full Text] [Related]
15. First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors.
Tsimberidou AM; Vo HH; Beck J; Shia CS; Hsu P; Pearce TE
JCO Precis Oncol; 2023 Jan; 7():e2200496. PubMed ID: 36701651
[TBL] [Abstract] [Full Text] [Related]
16. Beta-Caryophyllene Enhances the Anti-Tumor Activity of Cisplatin in lung cancer Cell Lines through Regulating Cell Cycle and Apoptosis Signaling Molecules.
Ahmed EA; Abu Zahra H; Ammar RB; Mohamed ME; Ibrahim HM
Molecules; 2022 Nov; 27(23):. PubMed ID: 36500446
[TBL] [Abstract] [Full Text] [Related]
17. [Surgical treatment of lung cancer in patients over 75 years old].
Rjabov AB; Pikin OV; Glushko VA; Kolbanov KI; Bagrov VA; Aleksandrov OA; Barmin VV; Martynova DE; Vorobyeva EY; Larionov DA
Khirurgiia (Mosk); 2022; (12):20-30. PubMed ID: 36469465
[TBL] [Abstract] [Full Text] [Related]
18. Targeting Cdc20 for cancer therapy.
Jeong SM; Bui QT; Kwak M; Lee JY; Lee PC
Biochim Biophys Acta Rev Cancer; 2022 Nov; 1877(6):188824. PubMed ID: 36243246
[TBL] [Abstract] [Full Text] [Related]
19. In Vitro Effect of Δ9-Tetrahydrocannabinol and Cannabidiol on cancer-Associated Fibroblasts Isolated from lung cancer.
Milián L; Monleón-Guinot I; Sancho-Tello M; Galbis JM; Cremades A; Almenar-Ordaz M; Peñaroja-Martinez J; Farras R; Martín de Llano JJ; Carda C; Mata M
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743206
[TBL] [Abstract] [Full Text] [Related]
20. Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/cdh1-dependent degradation of CtIP and PAF15.
Duan L; Perez RE; Calhoun S; Maki CG
Cancer Biol Ther; 2022 Dec; 23(1):65-75. PubMed ID: 35100078
[TBL] [Abstract] [Full Text] [Related]
[Next]
